Here's the skin-level science: Subcutaneous fat acts as scaffolding
Empagliflozin and risk of incident gout: analysis from the EMPagliflozin comparative effectiveness and safEty (EMPRISE) cohort study
The study also indicates a progressive trend, with Wegovy, recognized as the most potent GLP-1 RA, administered at the highest dose and renowned for its remarkable reduction in body weight
"Biologically, that population appears to be, on average, around five years older," said Michael Corley , a UC San Diego professor and lead researcher on the study
GLP-1 and GIP-based therapies may be appropriate for individuals with Type 2 diabetes, insulin resistance, or those who are overweight (BMI 2730+) with at least one weight-related condition such as high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease